1148 related articles for article (PubMed ID: 9017001)
1. Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5.
Mehta RG; Moriarty RM; Mehta RR; Penmasta R; Lazzaro G; Constantinou A; Guo L
J Natl Cancer Inst; 1997 Feb; 89(3):212-8. PubMed ID: 9017001
[TBL] [Abstract][Full Text] [Related]
2. Prevention of N-methyl-N-nitrosourea-induced mammary carcinogenesis in rats by 1alpha-hydroxyvitamin D(5).
Mehta R; Hawthorne M; Uselding L; Albinescu D; Moriarty R; Christov K; Mehta R
J Natl Cancer Inst; 2000 Nov; 92(22):1836-40. PubMed ID: 11078761
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention of mammary carcinogenesis by 1alpha-hydroxyvitamin D5, a synthetic analog of Vitamin D.
Mehta RG; Hussain EA; Mehta RR; Das Gupta TK
Mutat Res; 2003; 523-524():253-64. PubMed ID: 12628523
[TBL] [Abstract][Full Text] [Related]
4. Chemoprevention of chemically-induced mammary and colon carcinogenesis by 1alpha-hydroxyvitamin D5.
Murillo G; Mehta RG
J Steroid Biochem Mol Biol; 2005 Oct; 97(1-2):129-36. PubMed ID: 16051482
[TBL] [Abstract][Full Text] [Related]
5. Stage-specific inhibition of mammary carcinogenesis by 1alpha-hydroxyvitamin D5.
Mehta RG
Eur J Cancer; 2004 Oct; 40(15):2331-7. PubMed ID: 15454260
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and mechanism of action of 1alpha-hydroxy-24-ethyl-cholecalciferol (1alpha[OH]D5) in breast cancer prevention and therapy.
Hussain EA; Mehta RR; Ray R; Das Gupta TK; Mehta RG
Recent Results Cancer Res; 2003; 164():393-411. PubMed ID: 12899538
[TBL] [Abstract][Full Text] [Related]
7. Differentiation of human breast carcinoma cells by a novel vitamin D analog: 1alpha-hydroxyvitamin D5.
Mehta RR; Bratescu L; Graves JM; Green A; Mehta RG
Int J Oncol; 2000 Jan; 16(1):65-73. PubMed ID: 10601550
[TBL] [Abstract][Full Text] [Related]
8. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
[TBL] [Abstract][Full Text] [Related]
9. Selective biological response by target organs (intestine, kidney, and bone) to 1,25-dihydroxyvitamin D3 and two analogues.
Norman AW; Sergeev IN; Bishop JE; Okamura WH
Cancer Res; 1993 Sep; 53(17):3935-42. PubMed ID: 8395333
[TBL] [Abstract][Full Text] [Related]
10. Induction of differentiation by 1alpha-hydroxyvitamin D(5) in T47D human breast cancer cells and its interaction with vitamin D receptors.
Lazzaro G; Agadir A; Qing W; Poria M; Mehta RR; Moriarty RM; Das Gupta TK; Zhang XK; Mehta RG
Eur J Cancer; 2000 Apr; 36(6):780-6. PubMed ID: 10762752
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer.
Chen TC; Holick MF; Lokeshwar BL; Burnstein KL; Schwartz GG
Recent Results Cancer Res; 2003; 164():273-88. PubMed ID: 12899529
[TBL] [Abstract][Full Text] [Related]
12. 25-Dehydro-1alpha-hydroxyvitamin D3-26,23S-lactone antagonizes the nuclear vitamin D receptor by mediating a unique noncovalent conformational change.
Bula CM; Bishop JE; Ishizuka S; Norman AW
Mol Endocrinol; 2000 Nov; 14(11):1788-96. PubMed ID: 11075812
[TBL] [Abstract][Full Text] [Related]
13. Comparative effects of 1α-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 on transporters and enzymes in fxr(+/+) and fxr(-/-) mice.
Chow EC; Durk MR; Maeng HJ; Pang KS
Biopharm Drug Dispos; 2013 Oct; 34(7):402-16. PubMed ID: 23897575
[TBL] [Abstract][Full Text] [Related]
14. The effects of 1 alpha,25-dihydroxyvitamin D(3) on matrix metalloproteinase and prostaglandin E(2) production by cells of the rheumatoid lesion.
Tetlow LC; Woolley DE
Arthritis Res; 1999; 1(1):63-70. PubMed ID: 11056661
[TBL] [Abstract][Full Text] [Related]
15. Singly dehydroxylated A-ring analogues of 19-nor-1alpha,25-dihydroxyvitamin D3 and 19-nor-22-oxa-1alpha,25-dihydroxyvitamin D3: novel vitamin D3 analogues with potent transcriptional activity but extremely low affinity for vitamin D receptor.
Okano T; Nakagawa K; Tsugawa N; Ozono K; Kubodera N; Osawa A; Terada M; Mikami K
Biol Pharm Bull; 1998 Dec; 21(12):1300-5. PubMed ID: 9881643
[TBL] [Abstract][Full Text] [Related]
16. Growth inhibition of carcinogen-transformed MCF-12F breast epithelial cells and hormone-sensitive BT-474 breast cancer cells by 1alpha-hydroxyvitamin D5.
Hussain-Hakimjee EA; Peng X; Mehta RR; Mehta RG
Carcinogenesis; 2006 Mar; 27(3):551-9. PubMed ID: 16195238
[TBL] [Abstract][Full Text] [Related]
17. 25-Hydroxyvitamin D3 1alpha-hydroxylase expression in breast cancer and use of non-1alpha-hydroxylated vitamin D analogue.
Segersten U; Holm PK; Björklund P; Hessman O; Nordgren H; Binderup L; Akerström G; Hellman P; Westin G
Breast Cancer Res; 2005; 7(6):R980-6. PubMed ID: 16280049
[TBL] [Abstract][Full Text] [Related]
18. 25-Hydroxyvitamin D3 is a natural chemopreventive agent against carcinogen induced precancerous lesions in mouse mammary gland organ culture.
Peng X; Hawthorne M; Vaishnav A; St-Arnaud R; Mehta RG
Breast Cancer Res Treat; 2009 Jan; 113(1):31-41. PubMed ID: 18205042
[TBL] [Abstract][Full Text] [Related]
19. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
20. Differential antitumor effects of vitamin D analogues on colorectal carcinoma in culture.
Wierzbicka JM; Binek A; Ahrends T; Nowacka JD; Szydłowska A; Turczyk Ł; Wąsiewicz T; Wierzbicki PM; Sądej R; Tuckey RC; Slominski AT; Chybicki J; Adrych K; Kmieć Z; Żmijewski MA
Int J Oncol; 2015 Sep; 47(3):1084-96. PubMed ID: 26260259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
